Physician profile
Basel Channis
NPI 1982834594
$5,328.33
in general payments reported to CMS, 2019-2025
26 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $196 · 2021: $208 · 2022: $760 · 2023: $1,317 · 2024: $1,494 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,909 · Education: $40.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,908.79 |
| Education | $40.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $677.52 | 2023-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $594.24 | 2022-2025 | |
| Travere Therapeutics, INC. | $593.17 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $573.61 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $486.35 | 2019-2025 | Farxiga |
| Horizon Therapeutics Plc | $270.07 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $267.83 | 2020-2025 | Acthar |
| Novo Nordisk INC | $256.29 | 2023-2025 | Ozempic |
| Akebia Therapeutics INC | $215.07 | 2019-2024 | Auryxia, Vafseo |
| Daiichi Sankyo INC. | $212.39 | 2019-2025 | Injectafer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $187.43 | 2025 | |
| Alexion Pharmaceuticals, INC. | $178.34 | 2022-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $160.03 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $142.27 | 2022-2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $119.05 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $74.18 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $63.89 | 2024-2025 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.11 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $42.90 | 2019-2022 | |
| Glaxosmithkline, LLC. | $30.97 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $27.45 | 2022 | |
| Vifor Pharma, INC. | $26.95 | 2022 | |
| Genzyme Corporation | $23.97 | 2024 | |
| Cormedix INC. | $21.98 | 2025 | Defencath |
| Boston Scientific Corporation | $19.79 | 2023 | |
| Merck Sharp & Dohme LLC | $17.48 | 2024 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Channis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.